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ABSTRACT
Carbonic anhydrases (CA) are a family of enzymes that catalyze the rapid interconversion
of carbon dioxide and water to bicarbonate. Carbonic anhydrase II is the most abundant protein in
the cytosol. CA II inhibitors are emergent therapeutic targets for the development of antiglaucoma
agents. Glaucoma is a disease affecting large number of people and characterized by an elevated
intraocular pressure due to excessive secretion of aqueous humor. The enzyme CA II is responsible
for the secretion of aqueous humor. Isoforms of CA II such as CA IV and CA I are present in many
tissues and organs other than the eye. The commercially available CA inhibitors such as
Brinzolamide tend to inhibit CA II and other isozymes such as CA IV and CA I. This leads to
undesired side effects such as numbness and tingling of extremities, metallic taste, depression,
fatigue, etc. In order to avoid these side effects an isozyme specific inhibitor is required. Here, we
sought a novel DNA-based agent to inhibit specifically carbonic anhydrase II. Toward this goal,
an 86 base pair, single-stranded DNA aptamer library containing a 40 base pair variable region
was screened for CA II binding candidates, using ten rounds of positive and negative selection.
Positive selection rounds has been used to evolve aptamers of extremely high binding affinity
toward the target CA II whereas negative selection cycles were performed to determine the
specificity of the aptamers toward CA II. Next generation sequencing (NGS) revealed sequences
of the aptamer library. The most active anti-CAII aptamer had a random central sequence 5’-CGT
AGC TAT GAT ATT GATT GTT TTT AAA TCC ACC CG TGCA -3’ and was designated as
CA II inhibitory aptamer (CAII-A8). This aptamer was found to be isozyme specific inhibitor
determined by the enzymatic assay of carbonic anhydrase for Wilbur Anderson Units (EC 4.2.1.1).
CAII-A8 is the first CA II isozyme specific inhibitory aptamer to be described as an antiglaucoma
agent.
vi
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CHAPTER 1 : INTRODUCTION
1.1 Glaucoma
Glaucoma is an eye disease that damages the optic nerve due to high intraocular pressure
and leads to irreversible blindness. Usually Glaucoma has no symptoms at early stages which
makes the disease more dangerous by the time it is noticeable, the disease has already progressed
to the level that irreversible blindness has already occurred and the treatment becomes more
difficult. The most common type of glaucoma known as primary open angle glaucoma estimated
to affect 60 million people worldwide and more than 2.2 million people in the United States [1].
The risk factors of glaucoma are elevated intraocular pressure, a family history of glaucoma and
high blood pressure. Eye pressure greater than 21 mmHg is considered as high intraocular pressure.
A fluid called aqueous humor is continuously produced from the ciliary body and flows from
posterior to anterior chamber and leaves the eye through trabecular meshwork. Continuous
secretion and regulation of outflow of aqueous humor is very important to maintain the intraocular
pressure in the normal range. When this mechanism is interrupted, the fluid inside the eye builds
up and results in increased eye pressure, therefore causes glaucoma [2]. Routine examinations are
very important for protecting the eye. An early treatment can help to prevent irreversible blindness
due to glaucoma.

1.1.1 Types of Glaucoma
Glaucoma is categorized on the basis of the angle formed between the iris and the cornea.
This angle formation is important for the drainage of aqueous humor from the eye. Glaucoma is
mainly divided into two forms, open-angle glaucoma (OAG) and closed-angle glaucoma (CAG).
OAG is one of the most common form of glaucoma which is estimated to affect 75% of glaucoma
1

cases in the population. CAG and OAG is further divided into primary and secondary forms. In
the case of Primary closed-angle glaucoma (PCAG), the drainage canal of aqueous humor is
blocked by the iris where the iris is in contact with the trabecular meshwork. In secondary closedangle glaucoma (SCAG), the drainage angle becomes narrow or closed which prevents the outflow
of aqueous humor. In Primary open-angle glaucoma (POAG) there is no significant abnormality
in the trabecular meshwork but there are some problems with the cells of the trabecular meshwork
that prevents the trabecular meshwork from carrying out its normal functions. The result is that
the outflow of aqueous humor is slowed down. The fluid inside the eye builds up and causes the
pressure inside the eye to increase. Secondary open-angle glaucoma also occurs for other reasons
such as Pseudoexfoliation syndrome or use of steroids for long period of time [3]. Finally,
glaucoma can be further classified as congenital and juvenile glaucoma.

1.1.2 Aqueous Humor pathway
The regulation of secretion and drainage of aqueous humor are physiologically important
to maintain intraocular pressure (IOP). IOP is important to fill the eye and retain its shape as well
as optical properties of the eye. Flow of aqueous humor against resistance produces an average
IOP of 15 mmHg [4]. Aqueous humor secretion involves three important processes such as passive
diffusion and ultrafiltration and active secretion [4]. Passive diffusion takes place when lipid
soluble substances are transferred through the membrane which occurs between the capillaries and
the chamber. On the other hand, ultrafiltration involves passive flow of water and water-soluble
substances through the ciliary epithelial membrane. Active secretion is one of the most important
process in aqueous humor formation as this is considered to contribute 80% to 90% of total
aqueous humor secretion. Nonpigmented epithelial cell is the main site for active secretion [5].

2

The enzyme carbonic anhydrase which is present in nonpigmented and pigmented ciliary epithelial
body, facilitates the transport of bicarbonate ion through ciliary epithelium. Carbonic anhydrase
catalyzes the reversible hydration of carbon dioxide to form bicarbonate ions and protons as shown
by the following reaction [6]:
CO + H O
2

2

H CO
2

3

HCO + H
3

-

+

Formation of bicarbonate affects aqueous humor transport by affecting Na+, feasibly by
regulating the pH for optimal active ion transport [7]. Proper IOP is dependent on the regulation
of inflow and outflow of aqueous humor. When the drainage canal gets blocked, the fluid in the
anterior chamber builds up and elevates the intraocular pressure. High IOP damages blood vessels
and optic nerves.

Figure 1.1: Aqueous humor pathway [82].
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Figure 1.2: Aqueous humor flow in glaucoma patient [83].

1.1.3 Risk factors of Glaucoma
Several factors are associated with increase in risk for developing glaucoma such as age people over age 60 are at greater risk for glaucoma. Glaucoma can even develop in younger people
but the risk increases as we get older. Glaucoma can be inherited. So a family history of glaucoma
increases the risk of developing glaucoma. Race is another risk factor for developing glaucoma.
African-Americans are more likely to be at higher risk for developing glaucoma than Caucasians.
Asians and Alaskans at higher risk of angle-closure glaucoma. Japanese people have greater
tendency to develop low-tension glaucoma. People who have diseases such as diabetes, myopia,
long term steroid or cortisone use and severe eye injury have tendency to develop glaucoma as
well [8].

4

1.1.4 Signs and Symptoms of Glaucoma
Usually open-angle glaucoma is painless and it doesn’t have any clear symptoms. Due to
the lack of significant symptoms, glaucoma is not detected at early stage. That’s why regular eyecheckup is very important. The only signs are gradual loss of vision and changes in optic nerve. In
case of closed-angle glaucoma, the symptoms are characterized by severe eye pain, seeing halos
around lights, red eye, high IOP, nausea, vomiting, decrease in vision and dilated pupil. Acute
angle closure glaucoma patients need immediate attention [9].

1.1.5 Antiglaucoma agent
High intraocular pressure can be lowered with medications. Different classes of
medications are available to treat glaucoma. Various topical and systemic medications are
available as anti-glaucoma agent. Prostaglandin analogs increases uveoscleral outflow of aqueous
humor and thereby decreasing the accumulation of aqueous humor in the anterior chamber.
Prostaglandin drugs includes latanoprost, travoprost and bimatoprost increases the trabecular
drainage [10]. Beta-adrenergic receptor antagonist decreases IOP by decreasing the secretion of
aqueous humor from ciliary body epithelium. This class of drugs include timolol, levobunolol and
betaxolol. Alpha2-adrenergic agonist works by both decreasing aqueous humor formation and
increasing the outflow. Brimonidine and apraclonidine are examples of alpha2- adrenergic agonist.
Alpha agonists such as epinephrine decreases the secretion of aqueous humor by constricting the
blood vessels of ciliary body. Another class of anti-glaucoma agent known as miotic agents or
parasympathomimetics such as pilocarpine increases the drainage of aqueous humor by
constricting the ciliary muscle and the opening of the trabecular meshwork. Carbonic anhydrase
inhibitors decrease high IOP by decreasing aqueous humor formation. Aqueous humor production

5

is decreased by inhibiting the enzyme carbonic anhydrase II in nonpigmented ciliary body
epithelium [11].

1.2 CARBONIC ANHYDRASE

1.2.1 Introduction
Carbonic anhydrase (CA) is a family of enzymes that catalyzes the reversible hydration of
carbon dioxide to form bicarbonate ions and protons and they are catalytically one of the fastest of
all enzymes. The reaction catalyzed by carbonic anhydrase is [12]:
CO

2

+ HO
2

H CO HCO + H
2

3

3

+

They are ubiquitous metalloenzymes, they have zinc ion in their active site. There are five
different CA families such as α, β, γ, δ and ζ and they are found in a wide variety of organisms
such as vertebrates, algae, bacteria and plants. The most essential CAs are α-CAs as they are found
in humans and they play vital roles in our body [13,14]. Mammalian CA isozymes are divided into
four categories such as the CAs in the cytosol (CA I, CA II, CA III, CA VII, CA XIII), the CAs in
mitochondria (CA VA and CA VB), secreted CAs (CA VI) and CAs bound to membrane (CA IV,
CA IX, CA XII, CA XIV and CA XV) [15]. Among mammalian α-class CAs, CA II is the one of
the crucial enzyme and it was the most studied of the CA isoforms. It was first isolated and
characterized in 1993, CAII was first reported by Meldrum and Roughton when they discovered
an enzyme in an erythrocyte that catalyzed the interconversion between carbon dioxide and
bicarbonate ion. They play a vital role in many of the physiological processes such as respiration
and transport of CO /bicarbonate between lungs and metabolizing tissues, pH and CO
2

2

homeostasis, secretion of ions in different organs and tissues and biosynthetic reactions such as
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lipogenesis and gluconeogenesis, bone resorption, calcification, tumorigenicity, and many
physiologic processes [16,17].
1.2.2 Catalytic and inhibition mechanism of carbonic anhydrases
The zinc ion present in the active site of CA II is very important for its activity. The data
of X-ray structure revealed that the Zn ion is located at the bottom of a 15 A deep active site cleft
2+

o

and in coordination with three histidine residues (His 94, His 96, His 119) and a water molecule
[11,18,19]. The hydroxyl moiety of Thr 199 forms a hydrogen bond with the zinc bound water
molecule which in turn forms a bridge to the carboxylate moiety of Glu 106. These interactions
help to increase the nucleophilicity of the zinc bound water molecule and adapt the substrate CO

2

in such a way that it favors the nucleophilic attack. The strong nucleophile (hydroxide bound to
Zn ) attacks the CO molecule bound in a hydrophobic pocket which leads to the formation of
2+

2

bicarbonate ion in coordination with Zn . Later on, a water molecule displaces the bicarbonate ion
2+

and releases the bicarbonate ion into the solution. As a result, the enzyme becomes catalytically
inactive. In order to make the enzyme active, a proton transfer reaction from the active site to the
environment takes place which may be aided by active site residues or by the buffers present in
the medium [20].

Figure 1.3: Active site of human Carbonic Anhydrase II [84].
7

Figure 1.4: Schematic representation of the catalytic mechanism of carbonic anhydrases [85].
There are two main classes of carbonic anhydrase inhibitors which includes metal
complexing anions and the unsubstituted sulfonamides. Both the inhibitors exhibit similar
inhibition mechanism. They work by binding to the Zn ion in the active site of CAs by either
2+

replacing the non-protein zinc ligand or adding to the metal ion and producing trigonalbipyramidal species. The most important carbonic anhydrase inhibitors, sulfonamides in
deprotonated state binds to the Zn ion in a tetrahedral geometry. Metal complexing anions such
2+

as thiocyanate act by binding to the metal ion either in tetrahedral geometry or as trigonal
bipyramidal adducts [21,22].

8

Figure 1.5: Mechanism of carbonic anhydrase inhibitors such as sulfonamide and thiocyanate [84].

1.2.3 Role of Carbonic Anhydrase in aqueous humor secretion
The enzyme carbonic anhydrase plays a vital role in the secretion of aqueous humor and
inhibition of this enzyme will lead to reduction of aqueous humor secretion and pressure in
glaucoma patients. Carbonic anhydrase is found in nonpigmented ciliary body epithelium. We all
have a HCO storing system in the aqueous humor, based on the hydration reaction of carbon
-

3

dioxide CO + OH à HCO in the ciliary body epithelium. Carbonic anhydrase catalyzes this
-

2

3

-

reaction but the reaction without the enzyme proceeds at measurable rate both chemically and
physiologically. The secretory cells deliver OH ion to the luminal surface, and at the same time
-

CO is delivered from blood and cells [23,24]. 40% of Na transported is linked to HCO3 . Nascent
+

-

2

fluid is isotonic with respect to sodium, but HCO3 ion is much higher whereas Cl is in lower
-

-

concentration than in plasma. Inhibition of carbonic anhydrase removes about 70% of HCO3

-

concentration and 30% of Na concentration. Chloride concentration remains unchanged. The
+

decrease in Na uptake reduces the secretion of aqueous humor. Thus it is clear that the enzyme is
+

present in great amount of physiological needs and over 99% inhibition is necessary to produce a
pharmacological effect.
9

1.2.4 Carbonic Anhydrase inhibitors as antiglaucoma agents
Carbonic anhydrase inhibition by sulfanilamide was discovered by Mann AND Keilin.
[25]. Sulfonamides with CA inhibitory properties are mainly used as antiglaucoma agents,
antithyroid drugs and some anticancer agents [26]. Two types of sulfonamides are developed as
antiglaucoma agents: systemic and topical sulfonamides. Four systemic sulfonamides have been
used clinically for a long time: acetazolamide, methazolamide, ethoxzolamide and
dichlorophenamide. Systemic sulfonamides are efficient in reducing high intraocular pressure by
inhibiting the enzyme carbonic anhydrase II
and leads to 25 – 30% decrease of IOP, but the concern is that sulfonamide is susceptible to
isozyme CA II and CA IV. They indiscriminately inhibit CA isozymes present in tissues other than
that of the eye whereas the target should be only CA II for antiglaucoma effect. Inhibition of
various CA isozymes leads to entire range of side effects such as numbness, tingling of extremities,
metallic taste, depression, malaise, metabolic acidosis, etc. [13, 26]. The Fig 1.6 below displays
the inhibition data for sulfonamides against several CA isozymes abundant in organs such as the
eye, kidney, blood, lungs, CNS, etc.

10

Figure 1.6: CA isozymes, Their relative CO Hydrase activity, affinity for sulfonamide [81].
2

As systemic sulfonamides are not isozyme specific, it was a major concern to make it
isozyme specific in order to reduce side effects. To minimize the side effects the route of
administration was changed from systemic to topical. Thus topical sulfonamides were formulated
which is administered directly into the eye. The first topically acting sulfonamide is Dorzolamide
entered in clinics in 1995 [27], and the second drug Brinzolamide which is structurally related to
Dorzolamide entered in clinics in 1999 [29]. But none of the clinically used inhibitors proved to
be effective when administered topically in reducing elevated IOP. These two new drugs which
show much less side effects as compared to the systemic sulfonamides but they also inhibit
physiologically relevant CA isozymes (CA I and CA IV) present in ciliary epithelium of the eye.
Thus the goal of this research project is to develop an isozyme specific inhibitor which will only
inhibit CA II but not CA I and CA IV and reduces the high IOP by decreasing the secretion of
aqueous humor.

11

1.3 APTAMERS
Aptamers are short (usually 20 to 60 nucleotides) single stranded RNA or DNA
oligonucleotides with a specific and complex three-dimensional structure that are able to bind to
target molecules with high specificity and affinity. Binding of aptamers to the target molecule
results from structure compatibility which includes stacking of aromatic rings, van der Waals and
electrostatic interactions [30, 31].

1.3.1 Theory and History
In 1990 Professor Larry Gold and his graduate student Craig Tuerk developed the process
called Systematic Evolution of Ligands by Exponential Enrichment (SELEX) during an
experiment at the University of Colorado. The experiment’s results led to the concept that nucleic
acids can bind to a wide variety of targets ranging from simple inorganic molecules to large protein
complexes and entire cells [32]. Ellington & Szostak named the RNA molecule as “aptamer”
referring to the latin word aptus – meaning “to fit”, and the Greek word meros – meaning “region”
[34]. Aptamers are ligands with high affinity and specificity that are able to bind to functionally
important parts of their targets, hence acting as inhibitors [33]. SELEX is an efficient method for
producing a protein binding drug. This method relies on the ability of a DNA-binding protein to
select high affinity DNA ligands from a randomized pool of DNA sequences. SELEX is performed
over several rounds with each round resulting in increased enrichment of DNAs capable of binding
to the protein. This method enables to separate bound DNAs from unbound DNAs and the bound
DNAs are amplified to generate a new pool. This process is repeated until aptamers with desired
affinities are identified [35].

12

1.3.2 Technology

1.3.2.1 Random DNA oligonucleotide library
The starting point of SELEX is usually a chemically synthesized random oligonucleotide
library. The oligonucleotide libraries contains two fixed primer binding sites and a region of
randomized bases maximal 20 – 60 nucleotide in length. The primer binding sequences are
required for PCR amplification at every selection cycle. In order to obtain strongest binding
aptamers, the random pool must cover as much sequence space as possible [36]. The RNA or
ssDNA libraries are used in SELEX procedures. In principal, the specificity and the affinity of
ssDNA and RNA ligands is not different. The benefit of RNA aptamer is that they can be expressed
inside cells which may have significant importance in vivo experiments. On the other hand, DNA
aptamers are much more stable than RNA aptamers. Another potential advantage of DNA
aptamers over RNA aptamers is that the selection process is much simpler and faster. The RNA
aptamer selection needs reverse transcription and in vitro transcription. It also requires initial
transcription for producing the RNA library from the DNA library. In case of DNA aptamer
selections, these steps are not necessary . In addition, the cost of DNA aptamer production is lower
than that for RNA aptamers. That is the reason DNA aptamers have become more prevalent
recently [37].
The random region of ssDNA library is synthesized by adding the mixture of all four
deoxyribonucleic acid derivatives to the reaction mixture allowing the random incorporation of a
nucleotide into the growing molecule. The promoter sequence for the RNA polymerase of
bacteriophage T7 is introduced into the 5’ terminal region of the ssDNA library to generate an
RNA library, dsDNA is obtained by a polymerase chain reaction (PCR), and then an in vitro
transcription is carried out. The synthesis of random sequences are relatively cheap [38].
13

The size (n) of random domain determines the complexity of the library, which is
calculated as 4 (n is the number of positions in the random sequence. For example, the complexity
n

of a library with thirty-five fully randomized nucleotides is 4 or 10 . Enough randomized
35

21

nucleotides should be used to get a high affinity ligand and most probably a stable structure. So
far the successful aptamers selected in the SELEX experiments represents 1 in 10 to 10 of the
9
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molecules in the starting library [39].
Aptamers are chemically modified to achieve particular purposes such as to expand the
potential varieties of oligonucleotides, to introduce new features e.g. addition of functional groups
in order to provide new possibilities for the interaction with the target molecules, to improve the
stability of the aptamers and to increase their resistance to nucleases [40]. Typical modifications
include the 2’-position of the sugar in RNA libraries. The ribose 2’-OH group of pyrimidine class
nucleotide is substituted with a 2’-NH or F group, this shields the RNA from nuclease degradation
2

[41]. There is another technique applied to overcome the instability of aptamers is the creation of
spiegelmers. The idea of spiegelmers is that the aptamers composed of natural D-oligonucleotides
can be selected against mirror image targets, such as D-amino acid peptides rather than natural Lamino acid peptides. Once the aptamers are isolated, they can be chemically synthesized as Loligonucleotide and they are called Spiegelmer. They will bind to the natural L-amino acid peptide
targets [42]. As Spiegelmers are composed of unnatural monomers, they are insensitive to nuclease
degradation and have shown to be stable over 60 hours in biological fluids [42, 43].

1.3.2.2 Standard Selection Process (SELEX)
The standard SELEX procedure starts with subjecting the oligonucleotide library to any
target molecule. The oligonucleotide sequences in the library which binds to the target are
considered as aptamers. Non-binding aptamers are then separated from binding aptamers. Those
14

that binds to the target molecule are amplified by polymerase chain reaction (PCR) to enrich the
pool and then they are selected through several additional selection cycles. The amplification is
performed by PCR in the case of DNA, and by RT-PCR followed by in-vitro transcription in the
case of RNA. The number of high affinity binding molecules are reduced to a small number
through several rounds of selection and then the individual aptamers are isolated, sequenced and
analyzed.
The partitioning of the aptamer-target complex from non-specific molecules can be
achieved by various techniques. The most commonly used method for protein targets partitioning
is filtration through nitrocellulose filters [44]. The selection processes using nitrocellulose
membranes usually require up to 12-15 selection cycles. Alternatively, the use of functionalized
magnetic absorbent particles with a magnetic separation system has also been considered to be a
useful tool for the separation of protein and nucleic acids [45]. Also, using affinity tags like
glutathione S-transferase and streptavidin - derivative surfaces [46, 47] or column matrices like
sepharose can be used to reduce the number of selection cycles [48].
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Figure 1.7: General scheme of SELEX system [86].
The partitioning of the aptamer-target complex from non-specific molecules can be
achieved by various techniques. The most commonly used method for protein targets partitioning
is filtration through nitrocellulose filters [44]. The selection processes using nitrocellulose
membranes usually require up to 12-15 selection cycles. Alternatively, the use of functionalized
magnetic absorbent particles with a magnetic separation system has also been considered to be a
useful tool for the separation of protein and nucleic acids [45]. Also, using affinity tags like
glutathione S-transferase and streptavidin - derivative surfaces [46, 47] or column matrices like
sepharose [48] can be used to reduce the number of selection cycles. A negative selection against
the partitioning matrix is very important to get rid of the sequences that have affinity toward the
matrix [49]. During recent years, more effective separation method are reported, e.g. Capillary
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Electrophoresis (CE), Flow Cytometry (FC) [50], Electrophoretic Mobility Shift Assay [51],
Surface Plasmon Resonance (SPR) [52].

1.3.2.3 RNA and DNA SELEX
The basic process of in vitro selection is same for both RNA and DNA SELEX. In order to select
RNA aptamers, before starting the first round of SELEX, the random DNA oligonucleotide must
be converted into an RNA library. A particular forward primer flanked at the 5’-end comprising
of T7 promoter sequence and reverse primers are required to transform the ssDNA library into a
double stranded DNA (dsDNA) library by amplification. An in vitro transcription of dsDNA was
carried out by the T7 RNA polymerase and producing a randomized RNA library. In every cycle
of SELEX a reverse transcription of RNA aptamers should be done and afterwards the aptamer
library should be amplified by RT-PCR. For every cycle, the RNA library is produced by in vitro
transcription.
The procedure of DNA SELEX is much simpler since it involves only one PCR
amplification. The library can be used straight in the first cycle of the SELEX in case of DNA
aptamer selection. Forward and reverse primer resulting from the specific sequences at the 5’- and
3’- end enable amplification of the selected oligonucleotides in each SELEX round. After PCR
amplification, ssDNA preparation must be performed to generate a ssDNA pool for the next round.
Several methods are commonly applied for the generation of ssDNA. Double stranded DNA is
separated into single stranded DNA by streptavidin coated magnetic beads. A biotin residue is
introduced into one of the primers used for amplification, and the DNA strands are denatured with
streptavidin [53].
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Figure 1.8: Scheme of RNA SELEX [87].
Asymmetric PCR amplification is another method to generate ssDNA. In this process,
different ratios of primers are used and the major product is the single stranded DNA. As
asymmetric PCR progresses, the lower concentration reverse primer is producing double-stranded
DNA and the forward primer which is in excess amount continues to produce the target strand.
[31]. An enzyme digestion method is also applied to produce ssDNA. A phosphate group is
introduced into the 5’ – end of one primer and the dsDNA obtained by amplification is treated with
the lambda exonuclease that cleaves the phosphorylated strand of DNA [54]. Another method to
generate ssDNA can be done by adding hexaethyleneglycol (HEGL) spacer and an elongation of
some adenine nucleotides (polyA) at the 5’- end of the reverse primer. The HEGL turns as a
terminator for the Taq polymerase. The extension of the target strand stops, whereas the non-target
strand continues to grow. The two strands can be separated by electrophoresis under denaturing
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conditions [55]. Until now, a number of both DNA aptamers and RNA aptamers have been selected
against various targets. Investigation shows that there is no difference between RNA and DNA
aptamers in terms of affinity and specificity [49]. Therefore, DNA aptamers have become more
prevalent during recent years [56].

1.3.3 Aptamers and antibodies
Antibodies has been used most extensively for molecular identification for more than three
decades. Aptamers are commonly known as a replacement of antibodies as they overcome the
limitations of antibodies. There are some advantages of aptamers over antibodies such as the
thermal stability of aptamers. Oligonucleotides are more stable at higher temperature than
antibodies and are able to retain their structure during multiple denaturation at 95 C in each
o

selection rounds. However, proteins are irreversibly denatured at elevated temperature. That’s why
aptamers can be used under an extensive range of assay conditions. The production of antibodies
are time consuming and very costly because it includes screening of large quantity of colonies
[57]. Furthermore, immunoassays are needed to check the activity of the antibodies in each set,
because the functioning of the same antibody has the tendency to differ from batch to batch.
Conversely, aptamers can be synthesized with high precision and reproducibility. Selection of
aptamers are more cost effective than the production of antibodies. Besides, modifications of
aptamers are more easier and can be done to enhance their stability and resistance toward
nucleases. Moreover, signal moieties such as fluorophores and quenchers can be used to produce
biosensors. Aptamers are generally low-immunogenic, since our immune system cannot recognize
oligonucleotides as external substances. Nevertheless, antibodies are known to be immunogenic,
which prevents repeated dosing [58]. The FDA approved aptamer “Macugen” showed very little
immunogenicity when administered to monkeys in 1000-fold higher doses (this data was
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demonstrated by the Eyetech Study Group). Also, aptamers show a broad range of applications
toward some ions or small molecules which cannot be detected by antibodies [59].

1.3.4 Aptamers in diagnostics

1.3.4.1 Aptasensors
Aptasensors are biosensor elements and their structural component is the aptamer [60].
Aptamers can be chemically modified without influencing their affinity and also they can easily
be labelled to be used in diagnostics [61, 62]. Aptasensors can be classified into two main types,
optical and electrochemical aptasensors, (1) Optical aptasensors include aptamers labelled with
fluorescence, luminophore, enzyme, nanoparticles or aptamer with label-free detection systems
(e.g., SPR, Surface Plasmon Resonance) [63]. E.g. an RNA aptamer was selected and used as a
detector ligand in a sandwich assay to recognize vesicular endothelial growth factor (VEGF) [64].
(2) Electrochemical aptasensors depend on the immobilization of the aptamer on an electrode
surface. Then the binding conditions with their targets can be monitored by the electrochemical
current variations [65]. E.g. a novel electrochemical sensor system based on two different aptamers
recognizing different epitopes of thrombin was developed. The first aptamer was thiol-modified
and immobilized on a gold electrode for capturing thrombin while the second indicator aptamer
was labelled with a pyrroloquinoline quinone glucose dehydrogenase [66]. Several aptasensors
have been developed to detect microorganisms and viral proteins e.g. RNA aptamer chip was
successfully manufactured for detecting HCV core antigen [67] and also RNA aptamer developed
for the detection of the HIV-1 Tat protein [68].
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1.3.4.2 Flow cytometry
The binding of aptamers to their target proteins presented on either cell surfaces or
microspheres can be detected by flow cytometry. E.g. a fluorescently labelled DNA aptamer with
high affinity to human neutrophil elastase (HNE) was used to stain HNE-coated beads for flow
cytometry [69, 70] and also a fluorescently labelled RNA aptamer with a high binding affinity to
mouse CD30 proteins had been evaluated for human CD30 protein recognition on intact cells by
both, flow cytometry and fluorescence microscopy [71].

1.3.5 Aptamers in therapeutics
Aptamers have been proven to be a promising class of novel drug as they are characterized
by small size, low or no immunogenicity, high stability, high specificity and high affinity to their
targets. In addition, the synthesis and selection of aptamers is relatively easy and inexpensive.
Aptamers have been validated as therapeutics in the areas of anti-infective, anticoagulation, antiinflammation, anti-angiogenesis, anti-proliferation, and immune therapy [72]. Macugen, the first
FDA approved aptamer in 2004 that was used against macular degeneration disease [73]. A peptide
hormone ghrelin which is related to appetite and weight gain was used as a target molecule for the
development of spiegelmers.
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CHAPTER 2: OBJECTIVE
The goal of this research project is to select and characterize ssDNA aptamers
specifically binding to carbonic anhydrase II (CAII) and to evaluate a potential in vitro inhibition
of CAII activity that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate
ion. Inhibition of CAII has therapeutic application in the treatment of glaucoma, a disease affecting
a large number of people characterized by an elevated intraocular pressure (IOP). As isoforms CA
II/IV/I are present in many other tissues/organs, generally, systemic CA inhibitors possess
undesired side effects such as numbness and tingling of extremities, metallic taste, depression,
fatigue, etc. There’s no CA inhibitor reported yet which can specifically bind to CA II but not CA
IV and CA I.
In order to avoid above mentioned side effects, there should be an inhibitor which is
isozyme specific and has high affinity toward CA II. Toward this goal a ssDNA (N ) library will
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be screened by using SELEX method which includes ten rounds of positive selection against CA
II and negative selection against CA I, CA IV and Brinzolamide. Next-generation sequencing will
be used to sequence the aptamer candidates. Each sequence will be tested for inhibition of carbonic
anhydrase II activity by Wilbur-Anderson method and Surface Plasmon Resonance will be used
to analyze the binding affinity of an inhibitory aptamer. This could be the first step in the
development of CA II isozyme specific DNA aptamers.
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CHAPTER 3: METHODS & MATERIALS
3.1 CLONING AND EXPRESSION OF HUMAN CARBONIC ANHYDRASE II
The hCAII _pcDNA3.1+/C-(K) DYK construct (Genscript), was PCR amplified using Q5
high-fidelity DNA polymerase (NEB) with restriction enzymes specific primers. Restriction
digestion using Nde I (NEB) and Sac I (NEB) enzymes was performed for the PCR amplified
product and ligated to the corresponding sites in pET28a vector using 2X Instant sticky ligase Mix
(NEB). The ligation product was transformed in the DH5α bacterial cells using electroporation
method. Further, the colonies were inoculated and checked for the positive clones by performing
restriction digestion using Nde I and Sac I.
The hCAII_pET28a construct was transformed into BL21De3 cells by electroporation method of
transformation. The transformed cells were plated onto LB-Agar-Kanamycin (50 µg/ml) plate and
incubated at 37°C overnight to form colony forming units. A single colony was inoculated into 10
ml of Luria Bertani (LB) media along with 50 µg/ml of kanamycin, 0.5 mM ZnSO4 at 37°C for
overnight at 200 rpm. Overnight grown primary 10 ml culture was added along with 50 µg/ml
kanamycin and 0.5 mM ZnSO4 into 1 liter secondary culture. Cells were grown at 37°C until 0.60.8 at O.D.600 and further induced with 0.1 mM IPTG at 18°C for 16 hours. Cells were harvested
for 20 minutes at 6000 xg. and the cell pellet was resuspended into phosphate buffer and
centrifuged again at 3700 xg for 15 minutes. The final pellet was thawed and resuspended in 30
ml of lysis buffer (20 mM MOPS at pH 7.5, 10% glycerol, 1 mM PMSF) and sonicated for 5
minutes with 10 seconds on pulse followed by 10 seconds off pulse. DNAse (1 µg/ml) was added
to the sonicated cell lysate and gently stirred using magnetic stir bar on ice for 20 minutes. The
cells were centrifuged at 38,759 xg for 45 minutes at 4°C and the supernatant was loaded onto the
1 ml crude FF-His column (GE healthcare) pre-equilibrated with loading buffer (50 mM MOPs at
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pH 7.5) at 0.5 ml/min flow rate. Further, 15 column volume of loading buffer wash performed,
followed by the elution step using elution buffer (50 mM MOPs at pH 7.5, 500 mM Imidazole).
Elution was performed using 50 mM, 100 mM and 250 mM imidazole concentration. hCAII
protein was eluted in all the three concentrations of imidazole, with the purest in the 250 mM
imidazole fraction. The hCAII fractions were pooled and concentrated using 10 kDa cut-off
concentrator (Millipore Sigma). Buffer exchange step was performed using 50 mM MOPs pH 7.5
buffer to get rid of imidazole. hCAII protein was analyzed for its size as well as purity by
performing gel electrophoresis using 15% SDS PAGE gel. The protein concentration was
estimated by absorbance value at 280 nm using spectrophotometer (Eppendorf). The purified
protein was aliquoted, flash frozen in liquid nitrogen and stored at -80°C.

3.2 DNA TECHNOLOGY

3.2.1 Polymerase Chain reaction (PCR)
The PCR was first developed by Kary Mullis in 1983 [74]. PCR is a method to amplify a
segment of DNA to generate millions of copies of a DNA sequence. In molecular biology PCR is
one of the most widely used technique. It is an easy, cheap and most reliable way to replicate DNA.
A PCR reaction requires Taq polymerase, primers, template DNA, and nucleotides (DNA building
blocks). The ingredients are incorporated in a PCR tube and are put through repeated PCR cycles
of heating and cooling to allow the synthesis of DNA [75]. The basic steps of PCR includes
denaturation at 96 C. This step denatures the DNA strands and provides single-stranded template
o

for the next step. After denaturation annealing (55-65 C) is the next step where the reaction is
o

cooled to allow the primers to bind to their complementary sequences on the single stranded DNA
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template. Finally, extension at 72 C in which the temperature of the reaction is elevated so that the
o

enzyme Taq polymerase can extend the primers, synthesizing new strands of DNA.

Figure 3.1: Steps of Polymerase Chain Reaction [88]

3.2.2 PCR during aptamer selection

3.2.2.1 Symmetric PCR
It is same as the conventional PCR. Symmetric PCR was carried out in a 50 µl reaction
volume consisting of 50ng of ssDNA library, 1X Hot start PCR master mix, and equal ratios of
biotinylated forward and reverse primer. Symmetric PCR cycle was run for total of 25 cycles
(Table 3.1) and the temperature for denaturation was set at 94 C, annealing temperature was at
o

58 C and extension at 72 C.
o

o

25

Table 3.1 Symmetric PCR conditions
Step
Initial denaturation
Denature
Anneal
Extend
Hold
Total PCR cycles

Temperature
94 C
94 C
58 C
72 C
4C
25 cycles
o

o

o

o

o

Time
2 minutes
30 seconds
30 seconds
40 seconds
Indefinitely

3.2.2.2 Asymmetric PCR
Generation of ssDNA play key roles in ssDNA aptamer selection. Every new cycle must
be initiated with ssDNA library. An asymmetric PCR is done in order to achieve this goal. An
asymmetric PCR reaction involves amplification of one DNA strand in a double stranded DNA
template. Asymmetric PCR is similar to symmetric PCR, except that the amount of primer for the
targeted strand is much more than that of the non-targeted strand. As the asymmetric PCR
progresses, the lower concentration limiting primer is quantitatively incorporated into newly
synthesized double stranded DNA and used up. As a result, linear synthesis of the targeted single
DNA strand from the excess primer are formed after depletion of the limiting primer [76].

Figure 3.2: Steps of Asymmetric PCR [89].
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Asymmetric PCR was performed in a 25 µl reaction volume, which consisted 1 µl of
symmetric PCR product as an initial template, 20 pmol of nonbiotinylated forward primer and 1
pmol of biotinylated reverse primer (primer ratio was 20:1) and 12.5 µl of hot start PCR master
mix. Asymmetric PCR protocol was as set for 25 cycles in total and the temperature for
denaturation was at 94 C, annealing remparature was at 62 C which is little bit higher than
o

o

symmetric PCR and finally the extension temperature was at 72 C (Table 3.2).
o

Table 3.2: Asymmetric PCR conditions
Step
Initial denaturation
Denature
Anneal
Extend
Hold
Total PCR cycles

Temperature
94 C
94 C
62 C
72 C
4C
25 cycles
o

o

o

o

o

Time
2 minutes
30 seconds
30 seconds
40 seconds
Indefinitely

3.2.3 Streptavidin Magnetic Bead Isolation: purification of ssDNA
Magnetic beads coated with streptavidin are used to capture the biotin-tagged PCR product.
An asymmetric PCR generates mixtures of dsDNA along with ssDNA. Purification with
streptavidin coated magnetic bead is applied to eliminate dsDNA and other by-products from
asymmetric PCR product. At first, symmetric PCR using biotinylated primers was carried out to
provide enough templates for asymmetric PCR. Secondly, asymmetric PCR was carried out with
an abundant nonbiotinylated forward primer and a limited biotinylated reverse primer to generate
ssDNA. Thus, both dsDNA and the by-products produced during the PCR cycles carried biotin.
Finally, dsDNA and by-products were eliminated via streptavidin magnetic beads [77].
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Streptavidin-coated magnetic beads of 20 µl were washed three times with 50 µl of normal
saline and were captured using a magnetic bead after each wash. All asymmetric products were
transferred into the tube that contains the washed streptavidin-coated magnetic beads, and the
mixture was incubated at room temperature for 20 minutes with gentle mixing. Streptavidin-coated
magnetic beads were captured using a magnetic stand, and supernatants were carefully collected
without disturbing the streptavidin-coated magnetic beads.

3.2.4 Gel Electrophoresis
The symmetric, asymmetric and magnetic bead isolated products were separated on a 4%
agarose gel. Each sample (10 µl) with 5 µl of 6X loading dye was loaded onto a 4% agarose gel,
run in 1X TBE buffer at 80 volts for 70 minutes, and detected by SYBR gold nucleic acid gel stain.
The gels were visualized under UV light.

3.2.5 Ethanol precipitation of DNA
The extracted or eluted ssDNA from selection cycles were concentrated by a widely used
technique called ethanol precipitation. This method is carried out by adding salt (monovalent
cations such as sodium ions) and ethanol to the solution containing ssDNA. Ethanol efficiently
precipitates ssDNA in presence of salt. The precipitant of ssDNA is collected by centrifugation
followed by the removal of the supernatant [78].

Figure 3.3: Steps of ethanol precipitation of DNA [90].
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Ethanol precipitation of DNA protocol was started by adding 1/10 volume of 3M sodium
acetate to the solution containing ssDNA followed by the addition of 3 µL of glycogen. Equal
volume of isopropanol was added and incubated at -20 C overnight. The solution was centrifuged
o

at 14000 rpm for 15 minutes and then the supernatant was discarded. The ssDNA pellet was rinsed
with 70% ethanol. The solution was centrifuged again for 15 minutes. The supernatant was
discarded and the pellet was dissolved in water.
3.2.6 Determination of nucleic acid concentration
The concentration of dsDNA and ssDNA was determined by spectrophotometer at
wavelength 260nm (A ). The function describing the concentration to absorbance relation is the
260

Lambert-Beer law: OD = e* c* d
The optical density (OD) is the product of the substance specific extinction coefficient (e),
the concentration of the absorbing sample (c), and the optical path length in cm (d). The commonly
accepted absorbance to concentration conversion for nucleic acid is listed below:
dsDNA: 1 OD = 50 ug/ml
260

ssDNA: 1 OD = 33 ug/ml
260

The concentration of protein is determined at wavelength 280 nm (A ).
280
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3.3 IN VITRO SELECTION OF APTAMERS

3.3.1 Nitrocellulose filter partition method
Nitrocellulose membrane based SELEX was used for the selection of aptamers in order to
isolate unbound ssDNA aptamers from DNA-protein complexes. The principle of this method is
that most of the proteins nonspecifically binds to nitrocellulose membrane. Once the protein forms
a complex with a nucleic acid, the complex also binds to the nitrocellulose filter. As a result, the
unbound sequences are separated from the bound sequences.

Figure 3.4: Nitrocellulose filtration partition method [91].

3.3.1.1 Selection procedure
SELEX method was used for the selection of aptamers which involved both positive and
negative selections. The positive target of in vitro selection was CA II and the negative target was
CA I, CA IV and Brinzolamide. Total ten rounds of consecutive positive and negative selection
cycles were done. Generally, there is a competition between specifically and nonspecifically
binding nucleic acid sequences. Sequences with low affinity can be removed by increasing the
stringency of selection. A variety of parameters were used throughout the different rounds of
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cycles to increase the stringency, for example using different ratios of ssDNA: protein, decreasing
incubation time, and increasing number of washings with binding buffer.

Table 3.3: Conditions of stringency during SELEX rounds
Cycle

DNA (pmol)

CA II (pmol)

Incubation time
(mins)

No. of washings

1

1000

400

30

2

2

800

300

20

4

3

800

200

15

6

4

800

100

15

8

5

800

50

10

10

6

800

30

10

12

3.3.1.2 Pre-selection of aptamers
In order to refold aptamers into 3 dimensional structures, the ssDNA library was dissolved
in 150 µL of binding buffer and it was heated to 95 C for 15 minutes. After 15 minutes the ssDNA
o

library was cooled at room temperature for 10 minutes. The ssDNA library was filtrated through
nitrocellulose membrane filter in absence of positive and negative target to eliminate nitrocellulose
membrane binders.

3.3.1.3 Positive selection of aptamers
The pre-selected aptamers were incubated with the positive target CAII at 37 C for 30
o

minutes. The CA II-aptamer complex. The nitrocellulose membrane filter was soaked into the
reaction mixture. The mixture was allowed to incubate at 37 C for 30 minutes to let the complex
o
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to bind to the filter. The concentration of the unbound sequences left in the solution was measured
by spectrophotometry. The filter was removed from the reaction mixture and placed in a clean
tube. The filter was washed several times with 1 ml of binding buffer in order to get rid of loosely
bound and unbound sequences. Finally, the bound sequences were extracted from protein by
adding an elution buffer. In order to elute the sequences, the filter was cut into pieces and 200 µL
of elution buffer was added. The mixture was heated at 95 C for 5 minutes followed by vortexing.
o

Elution was done several times to make sure that all the tighter binding sequences are recovered.
At the end of elution step, the bound sequences were concentrated and precipitated by the method
called ethanol precipitation. The precipitated aptamers were resuspended in water and amplified
by symmetric PCR using biotinylated forward and reverse primer. To generate ssDNA asymmetric
PCR was done after symmetric PCR. The symmetric PCR product was used as a template for
asymmetric PCR where the reverse primer was biotinylated and the forward primer was
nonbiotinylated. The asymmetric PCR products contains mixtures of ssDNA and dsDNA. To
eliminate dsDNA and other by-products, asymmetric PCR product was purified by streptavidin
magnetic bead isolation.

3.3.1.4 Negative selection with CA I and CA IV
A negative selection with other CA isozymes (CA I and CA IV) was done to make sure
that the aptamers specifically binds to CA II but no other isozymes. In order to get isozyme specific
aptamers, positively selected aptamers were incubated with the negative target CA I and CA IV at
37 C for an hour. After incubation, the mixture was treated with a nitrocellulose filter. The bound
o

aptamers were discarded and the unbound aptamers were collected. At this stage the unbound
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aptamers are CA II binders only. This negative selection was done twice to make sure that all the
CA I and CA IV binders were eliminated.

3.3.1.5 Negative selection with Brinzolamide
Brinzolamide is a sulfonamide drug commercially available in the market used to treat high
intraocular pressure in patients with open angle glaucoma. It inhibits carbonic anhydrase II by the
interaction of sulfonamide group to the active zinc ion of carbonic anhydrase II.
The target of this research is to get not only CA II binders but also an inhibitory aptamer.
To achieve this goal, we have to make sure that the aptamers binds to the active site of carbonic
anhydrase II and inhibits its activity. Therefore, a negative selection was done with Brinzolamide.
At first the CA II and Brinzolamide was incubated for an hour at 37 C to allow the active site of
o

CA II to be occupied by Brinzolamide. Then the aptamers were added to the mixture and allowed
to incubate for one more hour at 37 C. The aptamers will bind to CA II other than the active site.
o

The binders were discarded and the unbound aptamers or active site binders were collected and
amplified. This negative selection was done twice to make sure we have eliminated all the nonactive site binders. Few more positive selections were done with these active site binders to get
higher affinity and more specific binding aptamers.

33

Figure 3.5: Schematic representation of negative selection in SELEX method [92].

3.4 EVALUATION OF APTAMERS BY NEXT GENERATION SEQUENCING
Next Generation Sequencing is a great platform where thousands to millions of DNA
molecules can be sequenced. NGS enables sequencing of multiple individuals simultaneously.
NGS facilitates the scientist to perform a wide variety of applications and study biological systems
with its ultra-high throughput, speed and scalability. NGS overcomes the limitations of Sanger
sequencing.
After 10 rounds of positive and negative selection, the selected aptamers were sequenced by
Next Generation Sequencing (NGS) from the company called Novogene. Next generation
sequencing requires high quality product. The symmetric PCR product after 6 positive selection
th

round was sent to Novogene for sequencing of the library. The table below shows the requirements
of the PCR sample for NGS.
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Figure 3.6: Requirements of quality and quantity of PCR sample for NGS
During NGS the quality of the crude PCR sample was determined. Once the DNA sample
passes the quality control test, the qualified DNA is cut into fragments by restriction enzyme. The
construction of the DNA library (Fig 3.7) is done through the process of end repairing, adding A
to tails, purification, PCR amplification and etc. libraries are sequenced by Illumina highthroughput sequencer with paired-end sequencing strategy. The qualified libraries are fed into
sequencers after pooling according to its effective concentration and expected data volume.

Figure 3.7: Principle of library construction in NGS.

35

3.5 BIOPHYSICAL ASSAYS

3.5.1 Enzymatic assay of Carbonic Anhydrase II
CA activity assay was performed using Wilbur-Anderson method. The assay was carried
out at 0 C using CO as a substrate following the pH variation due to the catalyzed conversion of
o

2

CO to HCO CO saturated water was made by adding CO from a tank into a 250ml Erlenmeyer
2

3

-.

2

2

flask filled with ddH2O. The flask was placed in an ice bath. The enzyme was suspended in 3ml
of 20 mM Tris buffer (pH 8.3) in a vessel that contained a pH electrode. The time taken for the pH
to change from 8.3 to 6.3 was measured on the addition of 2 ml ice cold CO -saturated water. A
2

blank reaction was performed by adding ice-cold water instead of the enzyme into 3 ml ice-cold
Tris buffer followed by the addition of the substrate CO . A negative control reaction was carried
2

out by adding the enzyme CA II in 3ml Tris buffer followed by CO substrate. A positive reaction
2

was carried out by adding an inhibitor Brinzolamide with CAII, Tris buffer and finally CO

2

substrate. A test reaction was done by the aptamers with CA II in Tris buffer and the CO substrate.
2
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CHAPTER 4: RESULTS
4.1 CLONING, EXPRESSION AND PURIFICATION OF HUMAN CARBONIC ANHYDRASE II
The hCAII _pcDNA3.1+/C-(K) DYK construct (Genscript), was PCR amplified using Q5
high-fidelity DNA polymerase (NEB) with restriction enzymes specific primers. A gradient PCR
was set up to ensure the annealing temperature of the primer. Restriction digestion using Nde I
(NEB) and Sac I (NEB) enzymes was performed for the PCR amplified product and ligated to the
corresponding sites in pET28a vector using 2X Instant sticky ligase Mix (NEB). The ligation
product was transformed in the DH5α bacterial cells using electroporation method. Further, the
colonies were inoculated and checked for the positive clones by performing restriction digestion

10 kbp
5 kbp
3 kbp
2 kbp
1.5 kbp
1 kbp
0.76 kbp
0.5 kbp
0.3 kbp

o

72 C

o

70 C

o

68 C

o

65 C

o

63 C

Ladder

using Nde I and Sac I.

0.78 kbp

Figure 4.1: PCR amplification of Nde I – hCAII – Sac I.
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Clone 4

Clone 3

Clone 2

Clone 1

Ladder

5.4 kbp pET28a
0.78 kbp hCAII

Figure 4.2: Restriction digestion of hCAII pET28a using Nde I and sac I.
The hCAII_pET28a construct was transformed into BL21De3 cells by electroporation
method of transformation. The transformed cells were plated onto LB-Agar-Kanamycin plate and
incubated at 37°C overnight to form colonies. A single colony was inoculated into 10 ml of LB
media along with 50 µg/ml of kanamycin, 0.5 mM ZnSO at 37°C for overnight at 200 rpm.
4

Overnight grown primary 10 ml culture was added along with kanamycin and 0.5 mM ZnSO into
4

1 liter secondary culture. Cells were grown at 37°C until 0.6-0.8 at O.D. and further induced with
600

0.1 mM IPTG at 18°C for 16 hours. Cells were harvested for 20 minutes at 6000 xg. and the cell
pellet was resuspended into phosphate buffer and centrifuged again at 3700 xg for 15 minutes. The
final pellet was thawed and resuspended in 30 ml of lysis buffer and sonicated for 5 minutes with
10 seconds on pulse followed by 10 seconds off pulse. The cells were centrifuged at 38,759 xg for
45 minutes at 4°C and the supernatant was loaded onto the 1 ml crude FF-His column preequilibrated with loading buffer at 0.5 ml/min flow rate. Further, 15 column volume of loading
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buffer wash performed, followed by the elution step using elution buffer. Elution was performed
using 50 mM, 100 mM and 250 mM imidazole concentration. hCAII protein was eluted in all the
three concentrations of imidazole, with the purest in the 250 mM imidazole fraction. The hCAII
fractions were pooled and concentrated using 10 kDa cut-off concentrator. hCAII protein was
analyzed for its size as well as purity by performing gel electrophoresis using 15% SDS PAGE
gel. The gene hCAII was successfully cloned in pET28a vector. It was expressed, soluble and

Supernatant
fraction
Purified hCA II

Total cell lysate

Ladder

successfully purified in 250 mM imidazole concentration.

250 kD
150 kD
100 kD
75 kD
50 kD
37 kD
25 kD
20 kD

29.2 kD

Figure 4.3: Expression and purification of hCA II_pET28a.
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4.1.1 Determination of hCAII activity
After expression and purification of hCA II, it was very important to determine the catalytic
activity of hCA II to make sure that the expressed hCA II is active. The catalytic activity of human
CA II was monitored by the enzymatic assay of Wilbur Anderson method. The assay was
performed at 0oC using CO2 as a substrate following the pH variation due to the catalyzed
conversion of CO2 to HCO3-. CO2 saturated water was made by adding CO2 from CO2 cartridges
into a 250ml Erlenmeyer flask filled with ddH2O. The flask was placed in an ice bath. The enzyme
was suspended in 3ml 20 mM Tris buffer (pH 8.3) in a vessel that contained a pH electrode. The
time taken for the pH to change from 8.3 to 6.3 was measured on the addition of 2 ml ice cold
CO2-saturated water. A blank reaction was done where water was used instead of the enzyme CA
II and negative control reaction was performed with Brinzolamide (BRZ) which is supposed to
inhibit the catalytic action of CA II and finally a test control reaction was carried out with CA II
at different concentrations to determine its catalytic activity. All the reactions were repeated three
times. The results (table 4.1) showed that increase in concentration of CA II decreases the time
taken for the pH to change from 8.3 to 6.3. The concentrations used was 1, 10, 50 and 100 pmol.
The lowest concentration (1 pmol) of CA II took 55 seconds to change the pH from 8.3 to 6.3
whereas the highest concentration (100 pmol) of CA II took only 19.4 seconds to bring the pH
down to 6.3 when compared with the blank reaction of 69.8 seconds. This assay confirmed that
the hCA II was catalytically active.
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Table 4.1: Carbonic anhydrase activity assay at different concentrations of CA II
No. of
reactions
1
2
3
4
5
6

Name of the reaction

Reaction

Blank
Test control
Test control
Test control
Test control
Negative control

CO + H O
CO + CA II (1pmol)
CO + CA II (10 pmol)
CO + CA II (50 pmol)
CO + CA II (100pmol)
CO + CA II + BRZ
2

2

2

2

2

2

2

Average time
(seconds)
69.8 ± 1.6
55.0 ± 0.8
48.0 ± 1.4
23.9 ± 1.2
19.4 ± 0.4
65.3 ± 1.2

Catalytic activity of hCA II
80
70

Time (seconds)

60
50
40
30
20
10
0
1

2

3

No. of reactions

4

5

6

Figure 4.4: Determination of catalytic activity of hCA II activity.
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4.2 IN VITRO SELECTION OF APTAMERS
A ssDNA library with random region of 40 was used for the selection of aptamers against
CA II. The random region was flanked by two primer binding sites of 23 nucleotide for PCR
amplification shown below:

5' - TAG GGA AGA GAA GGA CAT ATG AT - (N ) - TTG ACT AGT ACA TGA CCA CTT
GA - 3'
40

3’- AAC TGA TCA TGT ACT GGT GAA CT - 5’
Reverse primer

3’ – ATC CCT TCT CTT CCT GTA TAC TA – N40) – AAC TGA TCA TGT GGT GAA CT -5’
5’ – TAG GGA AGA GAA GGA CAT ATG AT – 3’
Forward primer

The first selection cycle was started with 10 sequences of aptamer library. Total of 6
24

rounds of positive selection was carried out with the target CA II and 4 rounds of negative selection
was done with CA I, CA IV and Brinzolamide. Aptamers after 10 round was isolated and
th

sequenced by next generation sequencing and the most abundant aptamers from the pool of
sequences were screened for inhibition assay.

4.2.1 Positive selection cycle
The first round of selection cycle was started with 1 nmol of ssDNA library incubated with
400 pmol of CA II. At the beginning of each cycle the ssDNA library were denatured and renatured
to allow folding of the DNA into a stable tertiary structure. The library was refolded in the binding
buffer (2 mM HEPES – NaOH, pH 7.5, 3 mM MgCl , 100 mM NaCl) at 95 C for 10 minutes.
2
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o

Positive selection cycles were carried out by incubating the target CA II with the library for 30
minutes at 37 C. The nitrocellulose filter was introduced into the reaction mixture to allow the CA
o

II-ssDNA complex to bind to the nitrocellulose filter and the unbound ssDNA will remain in the
solution which is meant to be discarded. Several numbers of washes were done to eliminate loosely
bound aptamers and finally the bound aptamers were eluted with an elution buffer (400 mM Naacetate, 5 mM EDTA, 7M urea) from the CA II-ssDNA complex. The eluted ssDNA was
concentrated by ethanol precipitation and a PCR amplification was performed to convert ssDNA
into a double stranded DNA. To convert the dsDNA to ssDNA, an asymmetric PCR was done
followed by streptavidin magnetic bead isolation to obtain purified ssDNA without any byproducts. The results (Fig 4.5, 4.6, 4.7) of 6 positive selection cycles displayed bright bands of
dsDNA and ssDNA for symmetric PCR and asymmetric PCR respectively in a gel electrophoresis
image. Finally bright bands of ssDNA were obtained after magnetic bead isolation. The gel images
confirms the production of ssDNA aptamers after each cycle and proves that all the selection cycles

100
75

th

6 cycle

th

5 cycle

th

4 cycle

rd

3 cycle

nd

2 cycle

st

1 cycle

Ladder

were successful.

dsDNA

50
35

Figure 4.5: Symmetric PCR amplification of 6 positive selection rounds.
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Figure 4.6: Asymmetric PCR of 6 positive selection cycles.
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ssDNA

Figure 4.7: Streptavidin magnetic bead isolation

4.2.2 Negative selection cycle
Negation selection was done with the negative targets CA I, CA IV and Brinzolamide. The
purpose selecting against CA I and CA IV is to make the aptamers CA II isozyme specific. In this
selection round the binders of CA I and CA IV were eliminated and the unbound aptamers were
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considered as CA II specific binders and were collected to continue the cycle. The reason of
selecting against Brinzolamide is to obtain CA II active site inhibitors. This selection cycle ensures
that the CA II binders specifically binds to the active site of CA II and inhibits its activity. Similar
to positive selection cycle, the negative selection cycles were started with refolding the ssDNA
library at the same condition. The library was incubated with the negative targets (CA I, CA IV,
Brinzolamide) and the negative target binders were eliminated and the unbound aptamers were
collected followed by PCR amplifications (symmetric and asymmetric PCR). The ssDNA product
after asymmetric PCR was purified by streptavidin magnetic beads. Each negative selection was

Magnetic bead isolation

Asymmetric PCR

Symmetric PCR

Ladder

Magnetic bead isolation

Asymmetric PCR

Symmetric PCR

Ladder

repeated twice.

300
200
150
100

dsDNA

75

ssDNA

50
35

(a)

(b)

Figure 4.8: Negative selection cycle.
(a) Negative selection cycle with CAI and CAIV. The products in magnetic bead isolation
step are ssDNA aptamers which specifically binds to CA II only. (b) Negative selection with
Brinzolamide. The ssDNA in magnetic bead isolation are the aptamers which binds to the active
site of CA II and making the CA II inactive.
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4.2.3 Optimization of PCR amplification
Aptamers are selected from libraries usually containing up to 10 different sequences by
15

an iterative process of binding, washing, elution, amplification and purification. It is important to
note that amplification of large oligonucleotide library with random region should be optimized
very carefully since over amplification may produce non-specific products and may lead to
reduced yield.
In PCR, DNA is amplified by a series of polymerization cycles comprising of three
temperature-dependent steps which includes denaturation of DNA strands, annealing of primers
and synthesis of DNA by the enzyme DNA polymerase. The quality and the yield of the products
depend on several parameters such as annealing temperature and number of PCR cycles. Primers
tends to bind non-specifically if the annealing temperature is lower than the optimum temperature.
However, primers are not even able to bind to the template if the temperature is significantly high.
Optimization of annealing temperature is critical especially when the ssDNA is treated with lot of
washing and elution buffer during selection rounds, making the DNA impure which ultimately
produces nonspecific products during PCR amplification. In order to obtain high quality and
quantity of PCR product, the annealing temperature was optimized by using gradient PCR. A
gradient of 53 C to 64 C was set for 30s. A PCR reaction was run under those selective temperatures
o

o

and then gel electrophoresis was performed to ensure the optimum annealing temperature.
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Figure 4.9: Optimization of annealing temperature.
The gel image (figure 4.9) displayed that the temperatures below 62oC produced some nonspecific amplification. In order to get rid by-products and to obtain pure dsDNA, 62oC was selected
as an optimum annealing temperature. Another round of PCR was performed with annealing

Ladder

temperature of 62oC to make sure no by-products are formed at this temperature.

100
75
50
35

dsDNA

Figure 4.10: PCR at optimum annealing temperature of 62 C.
o

The gel image (fig 4.10) of second round of PCR at annealing temperature of 62 C showed
o

no non-specific amplification. Therefore this temperature was selected as an optimum annealing
temperature for every selection round. Optimization of total number of PCR cycle is one of the
important parameter for successful PCR. Excessive cycling increases the opportunity for
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nonspecific amplification and errors. In order to achieve optimum number of PCR cycle, a gradient
PCR was set up using different number of PCR cycles such as 10, 12, 15, 20, 25, 30, 35 and 40.

10

12

15

20

25

35

30

40

Ladder

Number of PCR cycles

300
200
150
100
75

dsDNA

50
35

Figure 4.11: Optimization of total number of PCR cycle.
The result shows that at cycle number 40 high yield of dsDNA is obtained but it also
produced high level of non-specific amplification. Cycle number 35 and 30 showed the same
behavior. From cycle 25 to 10, the formation of non-specific amplification is greatly reduced but
it also produced less yield of dsDNA. The aim is to obtain high yield as well as good quality of
dsDNA product. To achieve this goal, 25 number of PCR cycles were selected for amplification.
This will ensure the product has no non-specific amplification and it will produce reasonable yield.

4.2.4 Optimization of generation and purification of ssDNA
The quality and yield of ssDNA plays a vital role in aptamer selection. The method of
purifying the PCR product by either gel extraction or PCR clean up by mini spin columns which
uses the silica membrane technology is not an efficient process as it leads to loss of PCR product
and the purity ratio (A /A ratio in spectrophotometer) of ssDNA is decreased. The generation of
260

230

DNA aptamer requires the conversion of dsDNA to ssDNA. There are various method to produce
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to ssDNA from dsDNA such as magnetic bead separation with streptavidin coated beads, lambda
exonuclease digestion and asymmetric PCR. Magnetic bead isolation method involves the binding
of dsDNA to the surface of magnetic beads with alkali, causing the aptamer tertiary structure to be
lost and impairing the efficiency and specificity of the aptamers.
The lambda exonuclease digestion method is designed to digest dsDNA tagged with a
phosphoglycerate-probed primer which is recognized by lambda exonuclease to remove the
complementary strand. This method provides very low yield of ssDNA. The drawback of
asymmetric PCR is that the ssDNA should be purified by gel extraction which leads to loss of PCR
products as well.
An indirect purification method was developed in order to achieve high yield and quality
of ssDNA. At first symmetric PCR was done to produce dsDNA where biotinylated forward and
reverse primers were used. Secondly, an asymmetric PCR was carried out using the symmetric
PCR product as a template with an excess non biotinylated forward primer and very limited amount
of biotinylated reverse primer. Asymmetric PCR produces a mixture of large quantity of ssDNA
and very less quantity of dsDNA. The dsDNA and the by-products after asymmetric PCR carried
biotin. Finally the dsDNA and the by-products were eliminated by streptavidin magnetic beads.
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SMB

SMB- by-products
SMB- dsDNA

Figure 4.12: A schematic representation of the indirect purification method [93].
The result (figure 4.13) of indirect purification method presents no by-products or dsDNA
after magnetic bead isolation step. This method was carried out at every cycle of SELEX round to

200
150
100
75

Magnetic bead isolation

Asymmetric PCR

Symmetric PCR

Ladder

obtain high quality and quantity of ssDNA.

dsDNA

50

ssDNA

35

Figure 4.13: PCR product purified by magnetic beads
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4.3 NEXT GENERATION SEQUENCING

4.3.1 Analysis of Next Generation Sequencing
The aptamers obtained from 10 round of selection was sequenced by next generation
th

sequencing (NGS). The analysis of the sequences provided total of 7 million sequences. Out of 7
million sequences, 6 millions were unique sequences. Sequences with 86 nucleotides were 450 K
and among 450 k , 388 k sequences have both constant primer region. From the pool of 388 k, 26
k sequences have random region of N . As our initial library was 86 nt with N random region,
40

40

we decided to screen sequences from the pool of N . The table 4.2 shows the 11 most abundant
40

sequences and the 11 aptamers were later screened for inhibition assay in order to find out the CA
II inhibitor.

Table 4.2: Aptamer sequences after 10 round of selection cycle
th

Name of
sequences
A1

Frequency

N variable sequence

7

CAACATCCCCGGCAATGGGTAACTCAAGCCATCTATAACC

A2

7

CATCCTGGACCCATACATTTACCTCATTATCACCGGCTGG

A3

6

GCCTGTTTTTGTAGATCATTGATAGCATACCCCCGGAGGG

A4

6

CACCCCTCTCAACTGTTATTACAACTGGCCGGTATCCGGA

A5

6

CACCGCATTGTAGATCCTATAGCCACTGTGTTTGATTGTG

A6

5

CCACACCACCTATAAGCACATAACTTAGCTATAATTCGGC

A7

5

GCACCCACCCAAATACCCTTAATCCAATTTTATTCCGGCG

A8

5

CGTAGCTATGATATTGATTGTTTTTAAATCCACCCGTGCA

A9

5

ACCGTACACCTCACATTGGTATTTAGCACTCTCCGATCCAT

A10

5

CACCCCTCGGACGTACCAGTATCGCTTTTATCGCTACCCA

A11

5

GCGATTACAACGTTCTTTACCTGTGACCCCACCGTTGCCA

40
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4.3.2 Carbonic anhydrase II inhibition assay with aptamers
The aptamers A1 to A11 were screened for inhibitory activity of CA II by the same method
of Wilbur Anderson electrometric assay. The time was measured for the pH to change from 8.3 to
6.3. A blank reaction was carried out with water and a test control reactions of aptamers (A1 to
A11) and a positive control with Brinzolamide (BRZ) were performed followed by a negative
control with CA II. Each of the experiments were repeated three times. An average time (seconds)
was calculated for the pH to change from 8.3 to 6.3. The concentration ratio of CA II : BRZ and
CA II: Aptamer used was 1:2.

Table 4.3: Screening of inhibition by 11 Aptamers
No. of
reaction

Reaction

Average time (seconds)

1

CO

70.2 ± 1.9

2

CA II

19.2 ± 0.8

3

BRZ

68.9 ± 0.9

+

4

A1

21.0 ± 1.6

-

5

A2

19.6 ± 1.2

-

6

A3

19.2 ± 1.6

-

7

A4

20.0 ± 1.2

-

8

A5

38.0 ± 1.4

+

9

A6

18.9 ± 0.9

-

10

A7

22.0 ± 1.2

-

11

A8

51.0 ± 0.8

+

12

A9

19.1 ± 0.4

-

13

A10

21.0 ± 0.9

-

14

11

21.0 ± 1.6

-

2
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Figure 4.14: Inhibition assay of Aptamers against CA II
When the 11 aptamer sequences were tested individually, two aptamers, A5 and A8 was
found to inhibit CA II. The time taken for Aptamer 5 to change pH from 8.3 to 6.3 was found to
be 43.0 ± 1.4 seconds and Aptamer 8 took 51.0 ± 0.8 seconds to drop the pH from 8.3 to 6.3
whereas the commercial drug Brinzolamide takes 66.7 ± 0.9 seconds to bring the same change. A5
and A8 were further tested for concentration dependent inhibition assay to make sure that both the
aptamers are inhibiting CA II with increasing concentration.

4.3.3 Concentration dependent inhibition assay of A8 and A5
In order to screen the concentration dependent inhibition of A5 and A8, different range of
ratios of CA II:A5 and CAII:A8 were set from lower to higher concentrations of A5 and A8. The
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assay started with a blank reaction where no CA II and inhibitor was added. The set of ratios were
1:0, 1:0.5, 1:1, 1:2, 1:4, 1:8 and 1:16.

Table 4.4: Concentration dependent inhibition assay of A8 and A5
No. of
reactions

CAII : A5

Average time
(seconds)

CAII : A8

Average time (seconds)

1

Blank

70.8 ± 1.2

Blank

71.4 ± 0.6

2

1:0

33.0 ± 0.9

1:0

19.6 ± 0.9

3

1:0.5

31.0 ± 0.5

1:0.5

40.0 ± 0.8

4

1:1

35.8 ± 1.2

1:1

43.0 ± 1.6

5

1:2

38.0 ± 1.9

1:2

50.6 ± 0.5

6

1:4

34.2 ± 2.0

1:4

66.3 ± 0.2

7

1:8

34.7 ± 0.5

1:8

70.6 ± 0.5

8

1:16

35.2 ± 0.9

1:16

71.6 ± 1.2
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Figure 4.15: Concentration dependent inhibition assay of A8.
The concentration dependent inhibition assay elicited increase in inhibition with increasing
concentration of A8. At zero concentration A8 did not show any inhibition and the reaction was
very fast due to the presence of enzyme CA II. When the concentration was increased from 0 to
0.5, the average time increased for pH to drop from 8.3 to 6.3. A great increase in time was noticed
at highest concentration of A8. This result showed that increase in concentration of A8 decreases
the rate of reaction catalyzed by the enzyme CA II because A8 binds to CA II and inhibits its
catalytic activity. On the other hand, A5 did not show a consistent increase in inhibition with
increasing concentration. So A5 was considered to be a poor binder and an inhibitor of CA II and
A8 was considered as a CA II inhibitor. Therefore A8 was selected for further investigations.
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4.3.4 Isozyme specific inhibition assay of A8
Aptamer 8 was found to inhibit CA II as a result of positive selection cycles. To make sure
that the aptamer specifically inhibits CA II but not CA I and CA IV, negative selections were done
to select out CA I and CA IV binding aptamers. Therefore the aptamers collected after 10 rounds
of positive and negative selection is considered to be CA II specific aptamer. To determine the
specificity of A8 toward CA II, an inhibition assay was performed with A8 against CA I and CA
IV. In this assay, we expect the aptamer to not to bind to CA I and CA IV and not to affect the rate
of reaction in presence of A8. The assay was started with a blank reaction where no enzyme and
inhibitor was added. A positive control was carried out with CA IV only without any inhibitor and
a negative control reaction with Brinzolamide was performed followed by the test control in
different concentration ratios of CA IV: A8 such as 1:0, 1:2, 1:4, 1:10. The same protocol was
followed for assay with CA I as well.
4.3.5 Inhibition of isozyme CA IV by A8
Inhibition assay was performed with A8 against CA IV where a positive and a negative
control reaction was carried out along with a blank reaction. In this assay CA IV enzyme was used
to catalyze the hydration of CO2. In presence of CA IV the reaction is very fast. We expect the
aptamer to be isozyme specific, so on the addition of A8, the rate of reaction will remain
unchanged.
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Table 4.5: Isozyme specific inhibition assay of A8 against CA IV
No. of
reactions
1
2
3
4
5
6

Ratio
Blank
CAIV:A8
CAIV:A8
CAIV:A8
CAIV:A8
CAIV:BRZ

1:0
1:2
1:4
1:10
1:2

Average time
(seconds)
71.3 ± 2.05
16.3 ± 1.7
14.3 ± 1.2
16.6 ± 1.7
17.7 ± 2.05
64.3 ± 1.6

Isozyme specific inhibition of A8 against CA IV
80
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70
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No. of reactions
Figure 4.16: Isozyme specific inhibition assay of A8 against CA IV

4.3.6 Inhibition of isozyme CA I by A8
An inhibition assay was performed with A8 against isozyme CA I following the same
protocol. Different concentrations of CA I: A8 was used like the previous assay with CA IV and
A8. The concentration ratios were 1:0, 1:2, 1:4, and 1:16. A negative control reaction was carried
out with Brinzolamide similar to previous assays.
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Table 4.6: Isozyme specific inhibition of CA I by A8
No. of
reactions
1
2
3
4
5
6

Ratio
Blank
CAI:A8
CAI:A8
CAI:A8
CAI:A8
CAI:BRZ

1:0
1:2
1:4
1:10
1:2

Average time
(seconds)
70.6 ± 1.8
17.6 ± 1.2
16.3 ± 1.2
17.3 ± 1.3
16.7 ± 1.6
62.6 ± 1.2

Isozyme specific inhibition of A8 against CA I
80
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No. of reactions
Figure: 4.17: Isozyme specific inhibition of CA I by A8
The data (fig 4.17) above explains there’s no inhibition of isozyme CA I by A8 when it is
compared with the positive control reaction. The rate of reaction did not changed at all on the
addition of A8. The time taken for pH to drop to 6.3 at highest concentration was 16.7 seconds
which shows similar behavior as positive control reaction. On the other hand, the time taken for
the negative control was 62.6 seconds. This assay confirms that A8 is very specific toward CA II
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but not CA I and CA IV. A8 doesn’t inhibit isozyme CA I and CA IV. Therefore A8 is considered
to be isozyme specific CA II inhibitor.

4.4 SECONDARY STRUCTURE PREDICTION OF A8
The secondary structure of the potential aptamer A8 was predicted by MFold algorithm
(developed by Dr. Michael Zuker). MFold predicts optimal and suboptimal secondary structures
of RNA and DNA using the energy minimization technique of Zuker. The varied conditions
entered into the Mfold programme were matched with selection criteria of the aptamers. Prior to
selection the aptamers were denatured and snap-cooled at 25 C to produce ssDNA aptamers. At
o

this step the aptamers folded into three-dimensional structure based on the sequences. Thus a
temperature of 25 C was entered into the Mofold programme to match the temperature of the snap
o

cooling process. During the denaturation process, the aptamers were in a binding buffer which
contained ions that may contribute to the aptamer structure. To match the buffer conditions, Mg

2+

and Na concentrations of 3 mM and 100 mM were entered into the Mfold algorithm respectively.
+

The N variable region of the aptamer (A8) was inputted into the Mfold algorithm to predict the
40

secondary structure. The sequence of A8 with its primer binding region is:
5’-TAGGGAAGAGAAGGACATATGATCGTAGCTATGATATTGATTGTTTTTAA
ATCCACCCGTGCATTGACTAGTACATGACCACTTGA -3’

59

Figure 4.18: Secondary structure prediction of Aptamer 8
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CHAPTER 5: DISCUSSION
Carbonic anhydrase inhibitors are widely used therapeutic agents in the management and
prevention of many diseases. This is mainly due to the wide distribution of the 14 vertebrate CAs
in many cells , tissues and organs where they play crucial role in many physiological functions.
Still, the available pharmacological agents are not perfect . They possess many side effects due to
their lack of selectivity toward different CA isozymes. One of the example is sulfonamide as
antiglaucoma agents which has susceptibility toward different CA isozyme. Thus development of
CA isozyme-specific inhibitor would be highly beneficial for obtaining novel types of drugs and
devoid of major side effects. Still, prospects for achieving such goals are not very optimistic due
to high similarity between the isozymes. The most similar isozymes are tend to be CA II and CA
IV which seems to be the predominant and most wide-spread isozyme in many tissues in which
specific inhibition is required.
In this research project, in vitro selection was carried out to identify ssDNA aptamers that
bound to Carbonic anhydrase II specifically and inhibited its catalytic activity. The ssDNA
aptamers were selected by SELEX method in which nitrocellulose filter partitioning was used to
separate ssDNA-protein complexes from unbound ssDNA. The pre-treatment of the filters with a
binding buffer effectively decreased the non-specific binding of ssDNA to the filters. The
negative-selection with nitrocellulose filter before the selection round removed the matrix binders
from the library.
There is no standard protocol for SELEX which can be suitable for all targets. Therefore
the conditions of the selection cycles were optimized according to the target properties and the
requirements of the selected aptamers. One of the important feature of oligonucleotide library
design is the length of the random region. The single-stranded oligonucleotide motifs can be built
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starting from 30 nucleotides [39]. Usually longer random region contributes to greater structure
complexity which is very important in target recognition and binding [79]. However, from
previous literatures it was found that the efficiency of aptamer selection decreases with random
region longer than 70 nt [80]. Therefore, in this research project ssDNA with random region of
40 nt was used for the selection of ssDNA aptamers against CA II. N40 random region was
considered to be ideal length as the complexity of the library is sufficient and the chemical
synthesis of such library is cost-effective.
Analysis shows that there is no significant difference between RNA and DNA aptamers in
terms of affinity and specificity [39]. Moreover, DNA aptamers have certain advantages over RNA
aptamers. The selection of DNA aptamer is much faster and easier than RNA aptamers. DNA
aptamers exhibit higher stability than RNA aptamers in a broad range of conditions including
biological systems which makes them more suitable for clinical applications. Thus, ssDNA library
was chosen instead RNA library.
The first round of selection cycle was started with 1024 sequences with 40 nt randomized
region. After 10 rounds of positive and negative selection and amplification, CA II-specific
targeted aptamers were isolated and were sequenced by next generation sequencing. After analysis
of raw data of NGS, the most abundant sequences were selected. The screening of aptamers for
enzymatic assay was started with 11 abundant sequences. The enzymatic assay of carbonic
anhydrase was performed by following the pH method (Wilbur-Anderson Unit). This method was
chosen to do the carbonic anhydrase enzymatic assay because this method resembles the real
biological system where the catalysis of CA takes place in the reaction of interconversion of carbon
dioxide and water to bicarbonate ion. At first the aptamers were tested for inhibition of CA II. One
of the aptamer (A8) showed inhibitory activity toward CA II out of 11 aptamer sequences. Another
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set of experiment was performed with A8 to determine its specificity toward CA II. Therefore A8
was introduced in the hydration reaction of CO2 where CA I and CA IV was the catalyst. No effect
of A8 on the activation of CA I and CA IV was observed. The reaction with A8 didn’t bring any
change in time for the pH to drop from 8.3 to 6.3 when compared with the negative control
Brinzolamide.
The most active anti-CAII aptamer had a random central sequence 5’-CGT AGC TAT
GAT ATT GAT TGT TTT TAA ATC CAC CCG TGCA-3’ and was designated as CA II specific
inhibitory aptamer (CAII-A8). This sequence can be folded into a common hairpin loop-stem motif
by secondary structure prediction. Therefore this research project offers the possibility to generate
anti-CAII aptamer which is an isozyme specific inhibitor and can have implication in the treatment
of glaucoma.
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CHAPTER 6: SUMMARY & FUTURE PROSPECTS
Carbonic anhydrase inhibitors are widely used therapeutic agents in the management of
many diseases. This is because of their wide distribution of CA isozymes in many cells, organs
and tissues where they play significant role in many physiological functions. The available CA
inhibitors possess many undesired side effects due to lack of their specificity toward different
isozymes. Thus development of isozyme-specific inhibitor

would be highly beneficial for

obtaining drugs, devoid of major side effects.
This research study focused on antiglaucoma agents, developing an isozyme specific
inhibitor which would inhibit CA II specifically in order to decrease IOP by reducing the inflow
of aqueous humor. The challenge was to discriminate between the isozymes CA I, CA II and CA
IV. Toward this goal, ssDNA aptamers were selected by SELEX method. Few rounds of negative
selection was done against the negative targets CA I and CA IV to make the aptamers isozyme CA
II specific. After 10 rounds of selection and next generation sequencing, aptamers were screened
for inhibition assay and one aptamer was found to inhibit CA II specifically. pH dependent
enzymatic assay (Wilbur Anderson) was done to determine the inhibitory activity and isozyme
specificity. To validate the inhibitory activity and isozyme specificity, further investigations
should be done such determining the binding affinity of A8 toward CA II by SPR. To make sure
A8 doesn’t have any binding affinity to CA I and CA IV, Kd value should be determined by SPR
as well. Once the Kd value determines its inhibitory activity and specificity we can find out the
mode of inhibition of A8 whether it is a competitive inhibitor or an uncompetitive inhibitor. Further
investigations such as X-ray crystallography can be done to study the molecular structure of the
aptamer-CAII complex. This will give as the opportunity to find out the inhibitory mechanism of
A8 to CA II . Also more aptamer sequences can be screened for inhibition and specificity to find
64

out an aptamer which may have better inhibitory activity than the commercial drug Brinzolamide.
The conclusion is that SELEX method can be employed to investigate aptamers of different
enzymes and can make it isozymes specific which may contribute to development of novel drugs
for may therapeutic applications.
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